Elinzanetant (Lynkuet): The Definitive Guide

What is elinzanetant?

Elinzanetant is a prescription nonhormonal medicine sold as Lynkuet. It blocks neurokinin 1 and neurokinin 3 receptors, usually abbreviated NK1 and NK3. The current US product treats moderate to severe hot flashes and night sweats due to menopause. The reviewed current UK and EU information also includes symptoms caused by adjuvant endocrine therapy related to breast cancer. Keep the indication attached to the country. [1], [2], [3]

The usual labeled amount is 120 mg, taken as two 60 mg capsules once daily at bedtime. That is not 120 mg per capsule. A label-described one-capsule adjustment applies with certain interacting medicines; it is not a universal “start with half” recommendation. The table below separates those contexts. [1], [2], [3]

Lynkuet does not supply estrogen or progestogen and is not contraception or a replacement for all menopause care. It can affect sleep-related symptoms, but can also cause daytime sleepiness, fatigue and dizziness. Liver testing, interaction review and pregnancy precautions are product-specific. This guide uses the current August 2026 US and UK information rather than assuming the original approval label is still complete. [1], [2]

What schedules are actually labeled?

The ordinary labeled pattern is two whole 60 mg capsules once daily at bedtime, with or without food. The 60 mg row is an interaction-specific clinician adjustment, not a universal titration ladder. No increase above the usual amount is supplied for breakthrough symptoms. Baseline suitability, pregnancy exclusion where relevant, medication review and local testing precede use; the ongoing need and benefit are reassessed. [1], [2], [3]

Which symptoms can improve?

The principal efficacy evidence concerns moderate to severe vasomotor symptoms. Trials measured frequency and severity using daily diaries, including daytime and nighttime episodes. A person’s treatment goal can focus on fewer interruptions, fewer sweat-related awakenings or better daily function. Meaningful partial benefit is different from complete disappearance of symptoms and should be recorded clearly. [1], [4]

OASIS 1 and 2 also found improvement in a sleep-disturbance questionnaire and menopause-related quality of life at 12 weeks. Those are trial endpoints in a defined population. They do not prove treatment of every cause of insomnia or a guarantee that bedtime dosing leaves no next-day impairment. Both benefit and daytime alertness belong in the review. [1], [4]

The current UK/EU AET indication is supported by a separate study population, not merely extrapolation from natural menopause. These patients were receiving specific endocrine treatments such as aromatase inhibitors or tamoxifen, with or without GnRH agonists. The UK SmPC asks for individual benefit/risk consideration when other cancer medicines are used. A broad claim that every oncology regimen is compatible would exceed the evidence. [2], [3], [6]

Other menopause goals remain separate. A nonhormonal hot-flash medicine is not local vaginal therapy, a bone-health plan or treatment for every cause of low mood. If systemic estrogen is separately considered, its benefits, risks and uterine-protection requirements still need clinical assessment. The reviewed UK/EU information does not recommend simply combining Lynkuet with systemic estrogen HRT because that combination has not been studied; local vaginal preparations are treated separately. [2], [3], [10]

What does dual NK1/NK3 blockade mean?

Neurokinins are chemical signals acting at specific receptors. Signaling in the hypothalamus contributes to temperature regulation, and menopause-related hormone changes can disrupt that balance. Elinzanetant blocks two receptor types, NK1 and NK3, rather than supplying a sex hormone. The mechanism explains why a nonhormonal treatment can address hot flashes; it does not demonstrate correction of a blood hormone deficiency. [1], [3], [4]

Fezolinetant is a different medicine that selectively blocks NK3. Dual blockade is not a proof of superiority, a doubling of benefit or a predictable sedation effect. A drug can have a promising mechanism while still needing controlled trials and real-world safety follow-up. Comparisons should use actual population, comparator, outcome and current warnings rather than the number of receptor names. [4], [10]

Blood estradiol or progesterone targets do not measure response to Lynkuet. Frequency, severity, sleep disruption, daily function and unwanted effects are more relevant clinical observations. No calculation converts its 120 mg amount into estrogen patch rates, paroxetine amounts or a fezolinetant tablet. Different molecules and formulations retain their own instructions. [1], [2], [4]

What did OASIS show, and for how long?

OASIS 1 and 2 randomized 796 postmenopausal women aged 40–65 to 120 mg elinzanetant or placebo. They had at least 50 moderate/severe hot flashes per week. In OASIS 1, 199 received drug and 197 placebo; OASIS 2 had 200 in each group. After 12 weeks, the placebo groups switched to elinzanetant, with total treatment follow-up extending to 26 weeks. Later drug exposure is therefore not a continuing placebo comparison. [1], [4]

At week 12, adjusted daily-frequency reductions in OASIS 1 were 8.66 with Lynkuet and 5.44 with placebo; OASIS 2 reductions were 9.72 and 6.48. The reported adjusted differences were 3.22 and 3.24 fewer daily episodes. Those estimates keep their trial baselines, modeled analysis and selected population. They are not a promise that every user will have three fewer episodes or that the product beats another drug studied elsewhere. [1]

The original report also found sleep-disturbance and quality-of-life improvement at 12 weeks. These results help define potential benefit, while completion and adverse-effect findings remind us that group means do not describe every experience. An individual who becomes too sleepy to function may judge the balance differently from one who sleeps better and remains alert. [4]

The current EU assessment describes supportive longer follow-up and a separate 474-person AET efficacy study. In that population, around eight fewer daily episodes at 12 weeks with treatment were compared with around four fewer with placebo. This rounded regulatory summary is not the exact estimate from the natural-menopause trials. Keeping the populations separate avoids treating a cancer-treatment study as a universal menopause result. [3], [6]

Endometrial safety was assessed in the US program, and no endometrial malignancy was identified in the described biopsy assessments. The label nevertheless reports hyperplasia-related abnormalities in four of 477 treated patients assessed, with different durations. Those data do not establish lifelong zero risk or protection during a separate systemic estrogen prescription. Unexplained bleeding still deserves clinical assessment. [1]

Which problems need prompt assessment?

Somnolence means sleepiness. Fatigue, dizziness, vertigo and near-fainting are among the nervous-system effects named in the US label. Across three OASIS trials, the label reports such effects in 11.9% with Lynkuet and 3.5% with placebo. This pooled figure is not the probability for a particular person and should not be transferred to another trial population. If affected, avoid driving or hazardous work until effects resolve. [1]

The US driving study found that average simulated driving performance did not reach the prespecified impairment threshold, but some participants were impaired after the initial dose and fewer after repeated dosing. An average finding cannot guarantee that you are safe to drive the next morning. Bedtime administration is not a workaround for severe daytime impairment. Discuss symptoms and demands such as commuting or shift work before continuing affected activities. [1]

New fatigue, poor appetite, nausea/vomiting, itching, yellow skin/eyes, pale stools, dark urine or abdominal pain can suggest liver injury. The US label advises immediate stopping and medical attention including tests if these occur. Its baseline and month-three plan does not mean wait three months with symptoms. The UK product also calls for tests when liver-injury symptoms occur. [1], [2]

Seizure has been reported, and current US/UK information advises caution with a seizure history or conditions lowering the seizure threshold. That is not permission to attribute any event to menopause or wait for adaptation. A seizure, collapse or other serious new neurological problem needs urgent medical assessment. The EU wording differs; its absence of an identical warning is not proof that a regional version is inherently safer. [1], [2], [3]

Pregnancy is a contraindication. US information says exclude pregnancy in those of reproductive potential and use effective contraception during treatment and for two weeks after stopping. These are US product instructions; do not silently substitute a universal after-stop interval across countries. Menopause symptoms alone do not establish infertility, especially during the transition. [1], [2], [3]

Why might the capsule count change?

CYP3A4 helps metabolize elinzanetant. Moderate inhibitors increase exposure and trigger a label-described 60 mg once-daily adjustment. The US label says return to the usual amount after stopping the inhibitor once three to five inhibitor half-lives have passed. A half-life is a drug-specific clearance interval; it is not a fixed three-to-five-day rule. The clinician or pharmacist identifies the actual drug and interval. [1], [2], [3]

Strong CYP3A4 inhibitors and grapefruit require avoidance in the US instructions; UK labeling contraindicates strong inhibitors. Strong/moderate inducers are avoided in US information, while UK wording emphasizes reduced exposure and monitoring of efficacy. St. John’s wort is among relevant inducer examples. Do not resolve differing labels by keeping whichever wording allows a desired combination. Use the actual product and jurisdiction. [1], [2]

Elinzanetant can also affect other medicines, including sensitive CYP3A4 substrates. Cancer treatment, immunosuppressants, sedating products and nonprescription supplements all belong in the medication review. UK/EU AET data are not a blanket interaction clearance for every anticancer agent. Record changes before and after treatment starts so that a new effect is not attributed solely to a menopause fluctuation. [1], [2], [3]

Public users ask about alcohol and next-day alertness. A favorable or unfavorable account does not establish a safe amount of alcohol with the medicine. Sleepiness and dizziness are actual labeled effects, so discuss the whole sedation burden and follow the professional’s advice. The guide does not provide a forum-derived alcohol allowance. [1], [7]

What if a bedtime dose is missed?

The US and UK labels say to take the next dose as scheduled the following day at bedtime, without two doses on the same day to make up the omission. Do not treat a breakthrough hot flash with an extra capsule. Capsule count follows the actual prescribed amount and interaction plan, not the severity of that evening’s symptoms. [1], [2]

Swallow capsules whole with water; do not cut, crush or chew them. A soft capsule is not two equal smaller doses. If swallowing is difficult, consult the pharmacist or prescriber about the product and alternatives rather than opening it to make an unverified preparation. Record actual use and refill gaps for review. [1], [2], [3]

One capsule can be an explicitly prescribed interaction adjustment. It should not be described as “half a capsule,” a generic titration technique or a community-validated adaptation plan. Keep the prescription amount, capsule strength and reason for an adjustment together, especially if an interacting medicine is later stopped. [1], [2]

How should the capsules and prescription be kept?

US Lynkuet is stored at 20–25°C with excursions permitted to 15–30°C. For the one-capsule adjustment, the US label specifically instructs exposing only one capsule in the paired blister cell and keeping the other in the original blister card/carton until the next dose. The UK product says do not store above 25°C and do not freeze. Follow the dispensed packaging’s own instructions. [1], [2]

Keep a record of brand, 60 mg capsule strength, capsule count, bedtime schedule, start date and any interaction-related adjustment. List liver-test arrangements and other medicines separately. A note saying only “120 mg menopause pill” loses the two-capsule distinction and may cause confusion when the amount changes. [1], [2]

Authorization, marketing and coverage differ. The current EMA overview establishes EU authorization, while the reviewed Australian AusPAR PI was approved with an earlier submission and warns it may be superseded. We do not present that PDF as proof of current October 2026 Australian instructions. Check the local current PI, prescription availability and reimbursement rather than relying on an approval announcement. [3], [5], [6]

What do the public experiences add?

One public thread describes perceived sleep and hot-flash benefit after switching products, while raising an alcohol-tolerability question. It is an account of one treatment experience, not a head-to-head trial against Veozah or evidence that other symptoms such as inflammation were treated. It helps identify useful questions about sleep and alertness. [7]

Another discussion describes returning symptoms after initial benefit and asks about combining medicines. A separate account reports troublesome daytime drowsiness and stopping because tolerability was poor. Together these selected accounts keep partial response, loss of perceived benefit and unwanted effects visible alongside favorable experiences. They cannot establish how often any outcome occurs. [8], [9]

Online self-adjusted capsule amounts and suggested combinations are not dosing authority. Severe impairment should prompt review rather than a compulsory adaptation period. A useful record includes what actually changed, whether benefit remained and what effects limited daily activities. No usernames, identifying narrative or satisfaction score is reproduced. [1], [7], [8], [9]

What should be monitored?

US instructions require baseline ALT, AST, alkaline phosphatase and total/direct bilirubin, with no initiation if ALT/AST or total bilirubin are at least twice the laboratory upper limit. Hepatic transaminases are reassessed three months after starting. New liver-warning symptoms require immediate stopping and medical assessment, not completion of that interval. [1]

The US label stops treatment if transaminases exceed five times the upper limit, or exceed three times with total bilirubin above twice the limit. Alternative causes of abnormal tests also need assessment. UK information recommends liver testing before starting and when symptoms suggest injury, without the same scheduled month-three wording; the current EU text must be read as its own product information. No universal calendar is inferred from these differences. [1], [2], [3]

At follow-up, review episode burden, sleep, actual daytime function, new medicines and capsule count. Ask directly about somnolence, fatigue, dizziness and neurological events rather than considering bedtime administration automatically well tolerated. A change in an inhibitor can change the prescribed amount and calls for a medication review, not an app-generated titration. [1], [2]

Long-term benefit is periodically reassessed as symptoms and goals change. Laboratory reports remain clinician-interpreted safety information. Hormone blood targets do not measure this medicine’s success, and a symptom graph cannot rule out an adverse effect or establish suitability during cancer treatment. [1], [2], [3]

What happens when treatment stops?

If liver-injury symptoms occur, the US label advises immediate stopping and medical assessment. Serious neurological events or major impairment also require prompt help. A general adaptation timeline cannot decide continuation, and this guide does not authorize restarting after a suspected serious reaction. Tell the clinician the actual last dose and every concomitant medicine. [1], [2]

For planned stopping because benefit is limited, symptoms have changed or access is difficult, agree on the next symptom-management plan. The reviewed labels do not provide a universal capsule-splitting taper or an alternate-day titration routine. If another medicine is introduced, its own indication, interactions and follow-up matter. Returning symptoms do not automatically mean the previous amount should be exceeded. [1], [2], [8]

US contraception instructions continue for two weeks after stopping in people of reproductive potential. This is separate from whether another hormone or cancer endocrine therapy is continued. Do not stop a cancer medicine or an endometrial-protection component solely because the hot-flash medicine changes. Coordinate the full plan and record each actual change. [1], [2], [3]

How does it compare with other options?

Fezolinetant and elinzanetant target related signaling but have different products, mechanisms, interaction pathways and current testing instructions. Milligrams cannot be compared as potency. Separate placebo trials do not prove one is superior for hot flashes, sleep or liver safety. The actual treatment burden and a person’s history are part of the comparison. [1], [4], [10]

Paroxetine’s menopause product is a low-dose SSRI with its own psychiatric, serotonergic and tamoxifen-related cautions. Gabapentin and behavioral interventions represent other approaches with different tradeoffs. The NAMS 2023 statement helps explain that broader menu but predates approved Lynkuet; it cannot substitute for August 2026 safety information. [10]

Hormonal treatment and local vaginal therapies address different goals when appropriate. Current UK/EU elinzanetant information distinguishes local vaginal preparations from unstudied systemic estrogen combinations. In cancer care, use the actual endocrine regimen, local indication and specialist assessment rather than the blanket phrase hormone-free is safe. Authorization and reimbursement are separate practical questions. [2], [3], [6]

Common questions

Is 120 mg one capsule or two?

The usual labeled amount is two 60 mg capsules taken together once daily at bedtime. The content of each capsule is 60 mg. One capsule is used in specified interaction-adjustment contexts; do not confuse capsule strength with prescribed daily amount. See the table. [1], [2] Keep capsule count and total amount together in the prescription record. A refill strength alone does not show whether the intended daily amount was taken. See the product schedules. [1] [2]

Can everyone start with one capsule?

No universal lower-starting schedule is supplied by the reviewed labels. The 60 mg row is attached to moderate CYP3A4 inhibitors. Selected online accounts do not validate a general adaptation or titration rule. Discuss a tolerability problem and actual interacting medicines with the prescriber. [1], [2], [9] The interacting medicine’s identity and elimination matter, including when it is stopped. Reassess with the prescriber rather than transferring a forum’s starting routine. See the medication interactions. [1] [2]

Are its liver tests the same as Veozah?

No. US Lynkuet calls for baseline testing and reassessment at three months, with immediate assessment for liver-warning symptoms. UK information recommends baseline and symptom-triggered testing. These are not Veozah’s US monthly-first-three-months and months-six/nine requirements. Use the actual product instructions. [1], [2] A warning symptom needs immediate action regardless of the routine month. Laboratory testing and symptom review are complementary parts of the actual local plan. See the monitoring plan. [1] [2]

Does improved sleep mean I am safe to drive?

No. Daytime sleepiness and other nervous-system effects can occur despite nighttime benefit. Average driving-study findings did not exclude impairment in individual participants. US instructions say refrain from driving or hazardous activities when affected until effects resolve. See risks. [1] Judge driving and work safety by individual functioning. A favorable group average does not clear a person who feels dizzy, unusually sleepy or unsteady. See the safety precautions. [1]

Is cancer-related use authorized everywhere?

No. The reviewed current UK/EU information includes AET-related VMS. The current US indication remains menopause-related VMS. Studied combinations and individual cancer history remain important even under a broader local indication. A regulator’s approval is not proof of reimbursement or compatibility with every therapy. [1], [2], [3], [6] The particular breast-cancer endocrine treatment still needs verification. A broader indication does not establish safety with every anticancer medicine or guarantee local availability. See the treatment goals. [1] [2]

Can I add it to systemic estrogen?

UK/EU information says that combination has not been studied and is not recommended, while treating local vaginal preparations separately. Do not add a capsule to a patch regimen solely from an online comparison. Review the complete plan and each product’s purpose. [2], [3] Keep each treatment goal explicit, including any endometrial protection during systemic estrogen. A partial symptom response is a reason for review, not automatic combination. See the medication interactions. [2] [3]

What if I cannot swallow the capsules?

They are to be swallowed whole, without cutting, crushing or chewing. Ask the pharmacist or prescriber about the actual formulation and alternatives. No verified opening or splitting method is supplied here. A one-capsule prescribed amount is not half a soft capsule. [1], [2], [3] Changing the formulation can change the treatment itself. The pharmacist can help identify suitable options, while the prescriber evaluates continuing symptoms and tolerability. See the product instructions. [1] [2]

Glossary

Terms used to read the product and evidence.

ALT

A liver-related enzyme measured in blood; an elevation needs clinical interpretation.

AST

An enzyme measured with other liver tests; it is not a symptom score.

Alkaline phosphatase

A blood-test enzyme used with other findings to assess liver or biliary problems.

Antagonist

A substance that blocks activity at a particular receptor.

Baseline

A measurement recorded before treatment begins.

Bilirubin

A pigment measured in blood; its elevation can accompany liver or biliary disease.

Boxed warning

A prominent US label warning about a serious risk.

CYP enzyme

An enzyme involved in medicine metabolism; inhibitors and inducers may alter exposure.

Cirrhosis

Advanced liver scarring; product restrictions may specifically name it.

Contraindication

A circumstance in which a product label says the medicine must not be used.

Drug-induced liver injury

Liver injury attributed to a medicine after assessment of other possible causes.

Endocrine therapy

Treatment affecting hormone production or action; cancer endocrine therapy is distinct from menopausal HRT.

Estrogen

A hormone used in some menopause treatments; these nonhormonal medicines do not replace it.

Hot flash

An episode of heat, often with flushing or sweating.

Hypothalamus

A brain region involved in temperature regulation and other bodily functions.

Inducer

A substance that increases enzyme activity, potentially reducing exposure to another medicine.

Inhibitor

A substance that reduces enzyme activity, potentially increasing exposure to another medicine.

Jaundice

Yellowing of skin or the whites of the eyes that needs assessment.

Least-squares mean

A model-adjusted average used in trial analyses, distinct from a simple raw average.

Median

The middle value in ordered data, different from the arithmetic mean.

Neurokinin receptor

A receptor responding to neurokinin signals; a drug may block a specified subtype.

Night sweat

Sweating episodes during sleep; a vasomotor episode is one possible cause.

Nonhormonal

A treatment that does not supply estrogen or progestogen; the term does not mean risk-free.

Off-label

Use outside the authorization for the exact product and jurisdiction.

Placebo

A comparison treatment without the trial medicine; its group can still improve.

Progestogen

A hormone-family treatment used for endometrial protection in many systemic estrogen regimens.

Randomized trial

A study assigning treatment groups by chance to help compare outcomes.

SSRI

A selective serotonin reuptake inhibitor; some specific products or amounts are used for hot flashes.

Serotonin

A chemical messenger affected by SSRIs and relevant to their interactions.

Tamoxifen

An endocrine medicine used in breast-cancer care; interacting treatments need review.

Upper limit of normal

The upper reference limit provided by the evaluating laboratory.

Vasomotor symptoms

Hot flashes and night sweats associated with menopause or a specifically assessed other cause.

How this guide was researched

We reviewed the full August 2026 US label and manufacturer PDF, full UK SmPC revised 3 August 2026, current consolidated EMA product information and overview, original open-access OASIS 1/2 report, historical Australian submission PI and NAMS 2023 statement. The current EU revision field has no specific date; the Australian file explicitly may be superseded. No current country rule is invented to fill either gap. [1]–[6], [10]

Protocol rows retain label, indication, country and interaction context. Natural-menopause and AET evidence remain separate. Current CNS, seizure, pregnancy and liver precautions are preserved with their jurisdiction; absence of identical wording elsewhere is not interpreted as proof of greater safety. Source-access notes distinguish original full text, regulatory summaries and selected public text.

Public accounts illustrate improvement, returning symptoms, nonresponse and unwanted effects without representative rates or prescribing authority. No private education or Academy lesson was accessed. Checked 2 October 2026.

Explore the sources